OTC Drug Manufacturer Owes 340B Entities Refunds, HRSA Audit Finds

CDMA makes private label OTC products for supermarkets and chain and local pharmacies.

The U.S. Health Resources Services Administration (HRSA) has ordered a Michigan-based manufacturer of over-the-counter (OTC) drugs that it audited to repay 340B covered entities because it did not offer its products at the statutory ceiling price.

HRSA posted

Read More »

United Therapeutics Delays its 340B Claims Data Upload Requirement

United Therapeutics pushed back a contract pharmacy claims data sharing requirement for 340B covered entities from today to Sept. 1.

United Therapeutics is holding off on requiring 340B covered entities to turn over their contract pharmacy claims data in order to get 340B pricing on drugs shipped to those pharmacies. The policy was supposed to take effect today. It will

Read More »

Breaking News

Breaking: Becerra, on 340B Pricing Denials, Tells House Panel, “Everyone Has to Follow the Law”

HHS Secretary Xavier Becerra told a House committee today "We are on this one" in reference to drug companies denying 340B pricing on their products.

U.S. Health and Human Services (HHS) Secretary Xavier Becerra told a member of Congress during a hearing this morning “We are on this one” when asked about six drug manufacturers’ denials of 340B drug discounts when covered entities use contract

Read More »

Takeda Pharmacy Partner Forcing 340B Pricing Opt-in/Opt-out Choice on Entities

Takeda business partner Foundation Care is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing “on eligible product purchases,” as a condition for obtaining a Takeda leukemia drug | Shutterstock

Drug manufacturer Takeda’s designated specialty pharmacy and distributor for its leukemia drug Iclusig is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing on purchases, as a condition for obtaining

Read More »

HRSA Signals It Will Rescind Trump’s 340B Insulin Rule

HRSA yesterday sent its proposal to rescind the Trump administration's 340B health center insulin pricing rule to the White House for review and approval. | Shutterstock

The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House for permission to rescind the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers

Read More »

Lilly Wants Judge To Schedule June Arguments in 340B Suit Against HHS

Drug maker Eli Lilly's motion yesterday in its 340B contract pharmacy lawsuit against HHS mainly covered the same ground as in its original January complaint. | Shutterstock

Drug manufacturer Eli Lilly yesterday asked a federal district judge in Indianapolis to schedule oral argument as soon as mid-June in its lawsuit challenging both a federal legal advisory opinion about 340B contract pharmacy and the 340B program’s new administrative

Read More »

North Dakota Is the Latest State to Pass a 340B Non-Discrimination Law

The North Dakota legislature (above) passed, and Gov. Doug Burgum (R) has signed, legislation prohibiting pharmacy benefit managers from discriminating against 340B covered entities or their contract pharmacies.

North Dakota Gov. Doug Burgum (R) has signed legislation prohibiting pharmacy benefit managers (PBMs) from discriminating against 340B covered entities or their contract pharmacies.

Burgum’s approval of H.B. 1492 on April 21 made North Dakota one of six states

Read More »

340B Non-Discrimination Bills Signed in Arkansas and Indiana and Passed in Tennessee

Tennessee lawmakers this week passed a 340B non-discrimination bill, sending it to Gov. Bill Lee for his signature.

Arkansas’s and Indiana’s governors have signed bills in recent days to prevent pharmacy benefit managers (PBMs) from discriminating against 340B covered entities, and a similar bill is awaiting the Tennessee governor’s signature.

Arkansas Gov. Asa Hutchinson (R) signed his state’s

Read More »

Multiple Developments in AstraZeneca’s 340B Contract Pharmacy Lawsuit

There were a handful of significant developments this week AstraZeneca's lawsuit to derail an HHS advisory opinion on 340B contract pharmacy.

The plain language of the 340B statute “explicitly requires drug manufacturers to offer 340B discounts to 340B covered entities regardless of whether the drugs are dispensed by the entity or by an outside pharmacy with which the entity has a

Read More »

Bristol-Myers Squibb Hires Apexus VP Richardson to Be its 340B Strategist

Long time Apexus vice president Katheryne Richardson is Bristol-Myers Squibb's new 340B strategist.

Katheryne Richardson, a long time Apexus vice president who was instrumental in launching its 340B University educational program and Apexus Answers call center, is moving to Bristol-Myers Squibb (BMS) to become the drug manufacturer’s 340B program strategist.

Her move to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live